China Securities Co.,Ltd.: Quarterly performance of medical device services continues to improve, and sector-wide opportunities are gradually emerging.

date
09:55 16/11/2026
avatar
GMT Eight
In the medium to long term, China's medical service penetration rate still has room for improvement, and we remain bullish long-term on chain medical service companies with differentiated positioning and leading regional medical service providers.
China Securities Co.,Ltd. released a research report stating that in 26Q3, the performance of multiple companies exceeded expectations, the performance inflection point for the device sector has emerged, it is optimistic about investment opportunities in 2027, and it recommends increasing allocation to the medical device sector. In the short term, individual stocks with improved performance present opportunities for performance and valuation repair. In the long term, device investment opportunities come from innovation, overseas expansion, and M&A integration; the sector's innovation and internationalization capabilities are being recognized, and valuations are being reshaped. Medical services: In the medium to long term, China's medical service penetration rate still has room for improvement, and the report is long-term positive on chain medical service companies with differentiated positioning and leading regional medical service providers. China Securities Co.,Ltd.'s main views are as follows: In Q3, multiple companies' performance exceeded expectations, and performance is expected to improve in 2027, with the sector effect gradually becoming evident Affected by factors such as consumables centralized procurement and higher medical compliance requirements, the A-share SW medical device index continued to decline from 2021 to 2024, rose first and then fell in 2025, rebounded in early 2026 and then pulled back. As the policy impact gradually clears, corporate performance is gradually recovering after strategic adjustments, and the device sector is ushering in a dual repair of valuation and performance. In Q3, Shanghai United Imaging Healthcare, APT Medical Inc., ShenZhen New Industries Biomedical Engineering, Shanghai Microport EP Medtech, and multiple other companies saw Q3 revenue or profit exceed expectations. Focus on companies with performance growth and continuous improvement in 2027, which are expected to achieve a dual boost in performance and valuation in the future. It is expected that the impact of centralized procurement and price reduction policies in multiple high-value consumables and IVD sectors will gradually clear by the end of this year or early next year, and sector-wide investment opportunities will gradually become prominent. Long-term positive on innovation and internationalization investment opportunities In the long term, medical device investment opportunities come from innovation, overseas expansion, and M&A integration. The sector's innovation and internationalization capabilities are being recognized, and valuations are being reshaped. Medical device products with globally competitive incremental innovation and breakthrough innovation are gradually being recognized, and some companies are actively strategically expanding their second growth curves and achieving high overseas business growth, with valuations rising. 1) Innovation: R&D investment and technological innovation are the prerequisites for companies to achieve domestic substitution and internationalization. Leveraging China's engineer dividend, industrial chain, and other advantages, it is relatively easy for medical device products to achieve incremental innovation, with many me-too and me-better products. Some Chinese medical device innovative products have gone from following and imitating to leading globally, and are gradually emerging internationally; after the innovative drug sector surged, medical device products with globally competitive incremental innovation and breakthrough innovation are gradually being recognized, and a group of companies are actively strategically expanding their second growth curves and achieving high overseas business growth, with valuations rising. Multiple U.S. device companies have achieved 10x or 100x growth since listing, and in the future China will also see globalized companies achieving multi-fold growth. 2) Overseas expansion: In the future, more and more investment opportunities in the medical device sector will come from internationalization, and more and more Chinese medical device incremental or breakthrough innovations are appearing on the international stage; the international business space is broader, multiple device companies achieved high overseas business growth in 26H1, the international business proportion will exceed domestic, and companies with large long-term international business space are also expected to see valuation reshaping. The global growth space for Chinese device companies is very broad, and as the proportion of international investors in the shareholder structure increases, valuations are expected to move closer to U.S. innovative device companies. 3) M&A: M&A is an important growth path for global medical device leaders, and in the future the bank will witness more and more industry M&A. Medical services In the medium to long term, China's medical service penetration rate still has room for improvement, and the report is long-term positive on chain medical service companies with differentiated positioning and leading regional medical service providers. The impact of healthcare reform policies on hospitals is related to multiple factors such as DRG, centralized procurement, and medical service price adjustments. As the policy direction gradually becomes clearer and is gradually implemented, leading private hospitals with strong technical strength and refined management are expected to achieve performance stabilization or repair in 2027. Consumer medical services In 2027, it is recommended to pay attention to the recovery on the demand side of medical services such as ophthalmology. With the implementation of the DRG/DIP 3.0 policy, the negative impact of medical insurance policies on businesses such as cataracts and basic eye diseases is expected to gradually weaken, and the demand side of consumer medical services such as refractive surgery is expected to gradually recover. Serious medical services In 2027, some industry leaders are expected to show a trend of moderate recovery, and revenue growth still needs to rely on increases in diagnosis and treatment volume, ramp-up of new hospital campuses, and expansion of new businesses. DRG/DIP 3.0 is in principle to be implemented before the end of March 2027, with grouping further refined and payment support for complex and severe cases and some innovative technologies more precise, which is expected to improve cost compensation for related cases; however, adjustments to disease group rules may also put pressure on the payment level of some cases, and attention still needs to be paid to hospital adaptation during the initial transition period. Risk warnings: Industry competition intensity stronger than expected; industry policy risk; R&D below expectations risk; approval below expectations risk; macroeconomic environment fluctuation risk; Middle East geopolitical risk.